Caban M, Koblmueller B, Groza D, Schueffl HH, et al. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo. Cancer Lett 2023;565:216237.
PMID: 37211067